Abstract 17P
Background
Esophageal adenocarcinoma (EAC) is a lethal cancer type rapidly increasing worldwide. Overexpression of the human epidermal growth factor receptor 2 (HER2) occurs in approximately one third of patients. However, small-molecule tyrosine kinase inhibitors, like lapatinib, show limited clinical benefits due to fast-developed drug unresponsiveness. The evolutionary driver of resistance remains largely unknown.
Methods
We generated reversible drug-tolerant persister and stable resistant cell lines through short- and long-term drug exposure. Time-course matched ATAC-seq and RNA-seq analysis were performed to dynamically decipher drivers for resistance development. Functional validation in vitro and in vivo using genetic and pharmacological approaches was conducted in both drug-sensitive and resistant cells. Furthermore, we detected the metabolic spectrum via flow cytometry and compared metabolic vulnerability through pharmacological disruption of critical enzymes involved between sensitive and resistant cells.
Results
Integrated multi-omics analysis revealed a high degree of NRF2 dependency during resistance acquisition. Inhibition of NRF2 incapacitated drug-tolerant persister development, and both naturally occurring and developed resistant cell lines showed consistent vulnerability to NRF2 inhibition. Conversely, NRF2 overexpression/activation promoted survival of sensitive cell lines from lapatinib toxicity by reprogramming metabolism to glutathione. Glutathione precursor supplementation rescued sensitive cells from lapatinib treatment, while disrupting the glutathione-conversion enzyme, GPX4, rapidly triggered cell death in resistant cell lines. In vivo, NRF2 inhibitor substantially suppressed the growth of lapatinib-resistant EAC xenografts, but tumor growth persisted in lapatinib-sensitive EAC-bearing mice, confirming the NRF2 vulnerability.
Conclusions
NRF2 is essential for acquiring resistance to ERBB2 inhibition, and it promotes a switch to glutathione dependency. These results offer a promising opportunity to tackle cellular adaptation and ensuing drug resistance in incurable EAC.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Wellcome Trust.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
21P - Hsa_circ_0009061 inhibits the progression of bladder cancer through the miR-889-3p/CPEB3 axis
Presenter: Minkang Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Exploring exportin-1 as a therapeutic vulnerability in lung squamous cell carcinoma
Presenter: Vidushi Durani
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Identification of HPSE as potential novel therapeutic target for lung adenocarcinoma patients
Presenter: Samuel Doré
Session: Cocktail & Poster Display session
Resources:
Abstract
24P - High-throughput plasma proteomics profiling in early breast cancer
Presenter: Isabella Lombardo
Session: Cocktail & Poster Display session
Resources:
Abstract
25P - Immunohistochemical analysis of ROR1 and BMI-1 expression in luminal breast cancer
Presenter: Sergey Vtorushin
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - Associations between cancer stem cells (CSC) markers and androgen (AR) and estrogen (ER) receptors expression in prostate cancer (PCa)
Presenter: Marina Puchinskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
27P - Proteomic profiling reveals organ-specific differences in metastases and identifies potential biomarkers for recurrence risk in localized colon cancer
Presenter: Blanca García-Micó
Session: Cocktail & Poster Display session
Resources:
Abstract
28P - Collagen-activated signalling pathway is significantly hypermethylated in high-grade serous ovarian cancer (HGSOC) patients treated with platinum-containing neoadjuvant chemotherapy (NACT)
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - Quantitative tissue analysis reveal adenylate kinase 2 protein signatures: Therapeutic target for meningioma
Presenter: Rashmi Rana
Session: Cocktail & Poster Display session
Resources:
Abstract
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract